Monopar Therapeutics MNPR
You should read the following discussion in conjunction with our financial statements as of December 31, 2025, and the notes to such financial statements included elsewhere in this Annual Report on Form 10-K.
Monopar Therapeutics Inc. ("Monopar," the "Company," "we," "us," and "our" and similar terms mean Monopar Therapeutics Inc. and its subsidiaries except where the context otherwise requires) is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Our Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Our radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers, that express urokinase plasminogen activator receptor ("uPAR").
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | $0 | $0 | $0 | $0 |
| R&D | $9.9M | $13.0M | $5.6M | $7.6M | $6.5M | $4.1M | $2.0M | $1.8M | $935.3K | $280.4K |
| SG&A | $6.8M | $3.2M | $3.2M | $2.9M | $2.6M | $2.4M | $2.4M | $1.6M | $1.2M | $912.5K |
| Total operating expenses | $16.7M | $16.2M | $8.8M | $10.5M | $9.1M | $6.5M | $4.3M | $3.3M | $16.6M | $1.2M |
| Operating income | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M | -$6.5M | -$4.3M | -$3.3M | -$16.6M | -$1.2M |
| Interest expense | — | — | $429.0K | $21.2K | $24.0K | $81.9K | $98.9K | $103.2K | $48.3K | $7.2K |
| Pre-tax income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M | -$6.3M | -$4.2M | -$3.3M | -$16.6M | -$1.2M |
| Income tax | $800 | $800 | $800 | $800 | $0 | $18.4K | $0 | $70.8K | $3.6K | $800 |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M | -$6.3M | -$4.2M | -$3.2M | -$16.6M | -$1.2M |
| EPS, basic | -1.85 | -4.11 | -3.04 | -0.83 | — | — | — | — | — | — |
| EPS, diluted | — | — | — | — | -0.73 | -0.58 | -0.45 | -0.35 | -1.89 | — |
| Shares, diluted (wtd. avg.) | 7.4M | 3.8M | 2.8M | 12.7M | 12.5M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M | $16.7M | $13.2M | $6.9M | $9.8M | $2.9M |
| Short-term investments | $60.9M | $45.5M | $6.5M | $12.2M | — | — | — | — | — | — |
| Total current assets | $140.5M | $60.3M | $7.3M | $13.2M | $20.5M | $16.8M | $13.2M | $7.3M | $9.1M | $2.1M |
| Total assets | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M | $16.9M | $13.4M | $7.3M | $9.9M | $2.9M |
| Accounts payable | $2.7M | $2.3M | $1.8M | $3.1M | $1.6M | $1.2M | $724.2K | $399.6K | $311.9K | $64.5K |
| Total current liabilities | $2.7M | $5.3M | $1.8M | $3.1M | $1.6M | $1.2M | $724.2K | $399.6K | $311.9K | $64.5K |
| Total liabilities | $2.9M | $5.3M | $1.8M | $3.1M | $1.6M | $1.2M | $724.2K | $399.6K | $311.9K | $64.5K |
| Retained earnings | -$89.5M | -$75.8M | -$60.2M | -$51.8M | -$41.3M | -$32.2M | -$25.9M | -$21.7M | -$18.4M | -$1.9M |
| Total equity | $137.8M | $55.0M | $5.6M | $10.1M | $18.9M | $15.7M | $12.6M | $6.9M | $9.6M | $2.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.2M | -$6.4M | -$7.9M | -$7.2M | -$7.3M | -$4.7M | -$3.0M | -$2.7M | -$2.6M | -$1.2M |
| Stock-based compensation | $4.8M | $1.1M | $1.9M | $1.6M | — | — | — | — | — | — |
| Investing cash flow | -$63.5M | -$14.3M | $4.9M | -$4.9M | $0 | — | — | — | — | — |
| Financing cash flow | $91.6M | $59.3M | $2.0M | $32.9K | $10.9M | $8.2M | $9.3M | -$206.3K | $9.5M | $1.3M |
| Buybacks | $35.0M | $0 | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-014183.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$1.2M | -$16.6M | -$3.2M | -$4.2M | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |